P. Jeffrey Conn
-
Vanderbilt inks collaboration with precision neuroscience company Neumora to continue development of investigational treatment for neuropsychiatric disorders
Vanderbilt University has signed an exclusive worldwide license and research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Read MoreFeb 22, 2022
-
Vanderbilt-discovered drug candidate for Parkinson’s disease enters clinical trials
Appello Pharmaceuticals Inc. begins trial of a drug candidate that improves relief from symptoms of Parkinson’s disease without debilitating side effects. Read MoreOct 6, 2021
-
Jeffrey Conn, founding director of Warren Center for Neuroscience Drug Discovery, named 2021 fellow of American Society for Pharmacology and Experimental Therapeutics
Jeffrey Conn, Lee E. Limbird Chair and professor of pharmacology, is among 16 scientists named 2021 fellows of the American Society for Pharmacology and Experimental Therapeutics. Selection as a fellow of ASPET is an honor bestowed on members who have demonstrated excellence in their efforts to advance pharmacology through scientific achievements, mentorship and service to the society. Read MoreSep 27, 2021
-
Conn, Calipari to receive major pharmacology awards
Two Vanderbilt University pharmacologists have won prestigious awards from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Read MoreFeb 6, 2020
-
Study explores potential new class of antidepressants
Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications. Read MoreNov 21, 2019
-
Vanderbilt, Boehringer Ingelheim announce partnership to develop therapies for psychiatric disorders
Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia. Read MoreJan 3, 2019
-
Investigational new drug for Alzheimer’s scheduled for first study in humans
Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center. Read MoreDec 27, 2016
-
Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt
Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation. Read MoreAug 15, 2016
-
Grant enhances mental illness drug research efforts
Research at Vanderbilt University Medical Center aimed at developing potential new treatments for major depressive disorder, general anxiety disorder and post-traumatic stress disorder got a big boost this week from The William K. Warren Foundation of Tulsa, Oklahoma. Read MoreJul 16, 2015
-
New schizophrenia drug candidates entering prep for first-in-human testing
The progression of new drug candidates for schizophrenia with partner Janssen Pharmaceutica is the latest evidence that a new collaborative model for drug discovery pioneered at Vanderbilt may help identify and develop innovative candidate drugs for treatment of major brain disorders. Read MoreDec 15, 2011